Cargando…

Neuroprotective Properties of 4-Aminopyridine

As an antagonist of voltage-gated potassium (Kv) channels, 4-aminopyridine (4-AP) is used as symptomatic therapy in several neurologic disorders. The improvement of visual function and motor skills and relieve of fatigue in patients with MS have been attributed to 4-AP. Its prolonged release formula...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietrich, Michael, Hartung, Hans-Peter, Albrecht, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931640/
https://www.ncbi.nlm.nih.gov/pubmed/33653963
http://dx.doi.org/10.1212/NXI.0000000000000976
_version_ 1783660334552186880
author Dietrich, Michael
Hartung, Hans-Peter
Albrecht, Philipp
author_facet Dietrich, Michael
Hartung, Hans-Peter
Albrecht, Philipp
author_sort Dietrich, Michael
collection PubMed
description As an antagonist of voltage-gated potassium (Kv) channels, 4-aminopyridine (4-AP) is used as symptomatic therapy in several neurologic disorders. The improvement of visual function and motor skills and relieve of fatigue in patients with MS have been attributed to 4-AP. Its prolonged release formulation (fampridine) has been approved for the symptomatic treatment of walking disability in MS. The beneficial effects were explained by the blockade of axonal Kv channels, thereby enhancing conduction along demyelinated axons. However, an increasing body of evidence suggests that 4-AP may have additional properties beyond the symptomatic mode of action. In this review, we summarize preclinical and clinical data on possible neuroprotective features of 4-AP.
format Online
Article
Text
id pubmed-7931640
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-79316402021-03-04 Neuroprotective Properties of 4-Aminopyridine Dietrich, Michael Hartung, Hans-Peter Albrecht, Philipp Neurol Neuroimmunol Neuroinflamm Views & Reviews As an antagonist of voltage-gated potassium (Kv) channels, 4-aminopyridine (4-AP) is used as symptomatic therapy in several neurologic disorders. The improvement of visual function and motor skills and relieve of fatigue in patients with MS have been attributed to 4-AP. Its prolonged release formulation (fampridine) has been approved for the symptomatic treatment of walking disability in MS. The beneficial effects were explained by the blockade of axonal Kv channels, thereby enhancing conduction along demyelinated axons. However, an increasing body of evidence suggests that 4-AP may have additional properties beyond the symptomatic mode of action. In this review, we summarize preclinical and clinical data on possible neuroprotective features of 4-AP. Lippincott Williams & Wilkins 2021-03-02 /pmc/articles/PMC7931640/ /pubmed/33653963 http://dx.doi.org/10.1212/NXI.0000000000000976 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Views & Reviews
Dietrich, Michael
Hartung, Hans-Peter
Albrecht, Philipp
Neuroprotective Properties of 4-Aminopyridine
title Neuroprotective Properties of 4-Aminopyridine
title_full Neuroprotective Properties of 4-Aminopyridine
title_fullStr Neuroprotective Properties of 4-Aminopyridine
title_full_unstemmed Neuroprotective Properties of 4-Aminopyridine
title_short Neuroprotective Properties of 4-Aminopyridine
title_sort neuroprotective properties of 4-aminopyridine
topic Views & Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931640/
https://www.ncbi.nlm.nih.gov/pubmed/33653963
http://dx.doi.org/10.1212/NXI.0000000000000976
work_keys_str_mv AT dietrichmichael neuroprotectivepropertiesof4aminopyridine
AT hartunghanspeter neuroprotectivepropertiesof4aminopyridine
AT albrechtphilipp neuroprotectivepropertiesof4aminopyridine